Vernalis buys back frovatriptan royalties and completes turnaround
This article was originally published in Scrip
Vernalis has reached an agreement with Paul Capital Healthcare to regain the right to all the royalties from Menarini's sales of frovatriptan (25.25% of net sales).
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.